

CHEMISTRY

A EUROPEAN JOURNAL

Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2007

Total Synthesis and Selective Activity of a New Class of Conformationally-Restrained Epothilones

Mamoun M. Alhamadsheh, Shuchi Gupta, Richard A. Hudson, Lalith Perera and L. M. Viranga

Tillekeratne*^[a]

[a] Department of Medicinal and Biological Chemistry, University of Toledo, Toledo, OH 43606, (USA)

Fax: (+1) 419 530-7946

E-mail: ltillek@utnet.utoledo.edu

Contents

General Methods	S2
Synthesis of Intermediates 3 and 4	S4
¹ H and ¹³ C NMR spectra for all compounds	S7
Antitumor Activity for 1b	S37
References for SI	S40

General methods.

All reactions were carried out under an argon or nitrogen atmosphere using dry solvents under anhydrous conditions, unless otherwise noted. Tetrahydrofuran (THF) and diethyl ether were distilled under nitrogen from sodium-benzophenone. The solvents used were ACS grade from Fisher. Yields refer to chromatographically and spectroscopically (¹H NMR) homogeneous materials, unless otherwise noted. Reagents were purchased from Aldrich and Acros, and used without further purification. Amano PS-D lipase was generously provided from Amano Enzyme USA. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.20 mm POLYGRAM® SIL silica gel plates (Art.-Nr. 805 023) with fluorescent indicator UV₂₅₄ using UV light and 15% sulfuric acid in ethanol solution and heat as visualizing agents. Normal phase flash column chromatography was carried out using Davisil® silica gel (100-200 mesh, Fisher). Preparative thin-layer chromatography (PTLC) separations were carried out on 1 mm, or 2 mm E. Merck silica gel plates (60F-254). NMR spectra were recorded on Varian INOVA 600, Varian VXRS-400, Bruker AC-F 300 MHz, or Nicolet NM-500 MHz (modified with a Tecmag Libra interface) instruments and calibrated using residual undeuterated solvent as internal reference. Coupling constants (*J*) were expressed in Hertz. Attached proton tests (APT) were performed to distinguish between different carbons in the ¹³C NMR spectra. The following abbreviations were used to explain the

multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and b = broad. Optical rotations were recorded on an AUTOPOL® III 589/546 polarimeter. High-resolution mass spectra (HRMS) were recorded on a Micromass LCT Electrospray mass spectrometer performed at the Mass Spectrometry & Proteomics Facility (The Ohio State University). (+)-Allyldiisopinocampheylborane solution in pentane was prepared by an adaptation of a procedure reported by Brown *et al.*^[1] Allylmagnesium bromide (5.82 ml of 1 M solution in ether, 5.82 mmol) was added dropwise to a well-stirred solution of (-)-*B*-methoxydiisopinocampheylborane (1.92 g, 6.062 mmol) in ether (35 ml) at 0 °C. After addition was complete, the reaction mixture was stirred at room temperature for 1h, and the solvents were pumped off under reduced pressure. The residue was extracted with dry pentane (3 x 13 ml) under nitrogen, and the stirring was discontinued to allow the precipitation of the MgBr(OMe) salt. The clear pentane supernatant was cannulated into another flask through a filtering funnel, and used without further purification.

Zinc borohydride (0.3 M solution in dry ether) was prepared by addition of saturated solution of anhydrous zinc chloride (12 g, 88.05 mmol, oven dried at 130 °C for 8 h under vacuo) in ether (50 ml) to NaBH₄ (8.1 g) in ether (150 ml).^[2,3]

General procedure for Mosher Ester: To a stirred solution of alcohol (1 equiv), DMAP (0.5 equiv), and triethylamine (3 equiv) in methylene chloride was added (*S*)-(+)- or (*R*)-(-)-*a*-methoxy-*a*-(trifluoromethyl)phenylacetyl chloride (MTPACl) (3 equiv) at room temperature. The resulting mixture was stirred overnight. The solution was diluted with ethyl acetate and washed with water, dried, and concentrated in vacuo. Purification by silica gel column chromatography will furnish the Mosher Ester.

6-Methyl-hept-6-enoic acid (7): *n*BuLi (10.8 ml of 2.5 M in hexanes, 27 mmol, 1.3 equiv) was added to a solution of methyltriphenylphosphonium bromide (9.7 g, 27 mmol, 1.3 equiv) in dimethyl sulfoxide (50 ml) at 0°C, and the mixture was stirred at room temperature for 1 h. It was then added to a solution of 6-oxo-heptanoic acid **6** (3 g, 20.82 mmol, 1 equiv) and *n*BuLi (8.33 ml of 2.5 M in hexanes, 20.82 mmol, 1 equiv) in THF (30 ml). The mixture was stirred at room temperature for 48 hr. Water was added and the mixture was acidified with 2 N HCl and extracted with methylene chloride (3 x 50 ml). The organic layer was washed with 10% aqueous sodium hydroxide solution. The aqueous layer was acidified with 2 N HCl and extracted with ethyl acetate (3 x 60 ml). The organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash column chromatography (10% EtOAc/hexanes) gave pure acid **7** (2.32 g, 78%) as a colorless oil: TLC R_f = 0.47 (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.69 (s, 1H), 4.65 (s, 1H), 2.34 (t, J = 7.8 Hz, 2H), 2.01 (t, J = 7.8 Hz, 2H), 1.69 (s, 3H), 1.64-1.58 (m, 2H), 1.50-1.44 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 180.7, 145.6, 110.4, 37.5, 34.2, 27.1, 24.4, 22.5.

6-Methyl-hept-6-enoyl chloride (8): To a solution of the carboxylic acid **7** (2.2 g, 15.5 mmol) in benzene (30 ml), was added oxalyl chloride (3 ml, 34.4 mmol, 2.22 equiv). A drying tube was placed on the flask and the reaction mixture was stirred for 90 min at room temperature before it was concentrated in vacuo. The crude acid chloride **8** was used in the next step without further purification: TLC R_f = 0.37 (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.69 (s, 1H), 4.67 (s, 1H), 2.88 (t, J = 7.8 Hz, 2H), 2.02 (t, J = 7.8 Hz, 2H), 1.74-1.66 (m, 2H), 1.69 (s, 3H), 1.58-1.46 (m, 2H); ^{13}C NMR

(100 MHz, CDCl_3) δ 173.9, 145.1, 110.7, 46.7, 37.3, 26.4, 24.8, 22.4.

(4S)-4-Isopropyl-3-(6-methyl-hept-6-enoyl)-oxazolidin-2-one (9):



To a solution of (*S*)-4-isopropyl-2-oxazolidonone (1.56 g, 12.1 mmol, 1 equiv) in THF (40 ml) at -78°C was added *nBuLi* (4.84 ml of a 2.5 M solution in hexanes, 12.1 mmol, 1 equiv). After 15 min acid chloride **8** (2.14 g, 13.3 mmol, 1.1 equiv) was added and the mixture was stirred for 30 min at -78°C and for 15 min at 0°C . Saturated aqueous ammonium chloride solution (10 ml) was added and the resulting slurry was concentrated in *vacuo*. The residue was diluted with ether and washed successively with saturated aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. Purification by flash chromatography (10% EtOAc/hexanes) gave imide **9** (2.94 g, 96%) as a colorless oil: $[\alpha]^{22}\text{D} = +66.7$ ($c = 0.6$, CHCl_3); TLC $R_f = 0.40$ (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.68 (s, 1H), 4.66 (s, 1H), 4.43-4.40 (m, 1H), 4.25 (t, $J = 9.0$ Hz, 1H), 4.19 (dd, $J = 3.0$ Hz, 9.0 Hz, 1H), 3.01-2.83 (m, 2H), 2.38-2.32 (m, 1H), 2.02 (t, $J = 7.8$ Hz, 2H), 1.69 (s, 3H), 1.67-1.61 (m, 2H), 1.51-1.46 (m, 2H), 0.90 (d, $J = 7.2$ Hz, 3H), 0.85 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.5, 154.3, 145.8, 110.2, 63.6, 58.6, 37.7, 35.6, 28.6, 27.2, 24.3, 22.6, 18.2, 14.9; HRMS (ESI): m/z : calcd for $\text{C}_{14}\text{H}_{23}\text{NO}_3 + \text{Na}^+$ 276.1576; found 276.1567 [$\text{M} + \text{Na}^+$].


(2S)-2,6-Dimethyl-hept-6-enal (3): As reported by Schinzer *et al.*^[4]: $[\alpha]^{22}\text{D} = +11.8$ ($c=0.5$, CHCl_3); TLC $R_f = 0.64$ (silica gel, 25% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 9.56 (d, $J = 1.8$ Hz, 1H), 4.66 (s, 1H), 4.62 (s, 1H), 2.34-2.28 (m, 1H), 1.98 (t, $J = 7.8$ Hz, 2H), 1.69-1.62 (m, 4H), 1.48-1.27 (m, 3H), 1.05 (d,

$J = 6.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 205.3, 145.4, 110.4, 46.4, 37.8, 30.2, 24.9, 22.4, 13.5.

(5S)-5,7-Bis-(tert-butyl-dimethyl-silanyloxy)-4,4-dimethyl-heptan-3-one (4): Sodium borohydride (570 mg, 15.4 mmol, 2 equiv) was dissolved in methylene chloride (175 ml) and dry ethanol (75 ml). The mixture was cooled to -78°C for 15 min after which a solution of aldehyde **10**^[5] (2.2 g, 7.7 mmol, 1 equiv) in methylene chloride (5 ml) was added. After stirring for 1 h water (6 ml) was added and the reaction mixture was allowed to warm to room temperature. Methylene chloride (400 ml) was added and the mixture was washed with saturated aqueous sodium bicarbonate before it was dried over anhydrous sodium sulfate and concentrated in vacuo to give crude alcohol mixture **11** and **12**. The crude alcohol mixture was dissolved in methylene chloride (40 ml) and cooled to 0°C . Imidazole (3.14 g, 46.15 mmol, 6 equiv) and *tert*-butyldimethylsilyl chloride (3.47 g, 23.1 mmol, 3 equiv) were added and the reaction mixture was stirred at room temperature for 16 hr. Saturated aqueous ammonium chloride (30 ml) was added and the layers were separated. The aqueous layer was further extracted with ethyl acetate (3 x 30) and combined organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash chromatography (1% - 5% EtOAc/Hexanes) gave the bis(silylether) **4** (2.5 g, 81% over two steps) as a colorless oil: $[\alpha]^{22}_D = -7.4$ ($c = 1.8$, CHCl_3); TLC $R_f = 0.70$ (silica gel, 20% EtOAc/hexanes); ^1H NMR (600 MHz, CDCl_3) δ 4.06 (dd, $J = 7.6$ Hz, 3.0 Hz, 1H), 3.62-3.54 (m, 2H), 2.57-2.41 (m, 2H), 1.56-1.42 (m, 2H), 1.09 (s, 3H), 1.02 (s, 3H), 0.99 (t, $J = 7.0$ Hz, 3H), 0.86 (s, 9H), 0.85 (s, 9H), 0.07 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H), 0.002 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 215.8, 73.6, 60.3, 53.2, 37.5, 31.8, 26.3, 26.1, 22.4, 20.2, 18.5, 18.4, 7.9, -3.8,



-5.1; HRMS (ESI): m/z : calcd for $C_{21}H_{46}O_3Si_2 + Na^+$ 425.2883; found 425.2885 [$M + Na^+$].






STANDARD PROTON PARAMETERS
Pulse Sequence: $\pi/2\pi\pi/2$
Solvent: CDCl_3
Ambient temperature
INNOVA-600 "innova600"

Jun 14 2004



136-00000000


Aug 15 2000



```



Pulse Sequence: apt
Solvent: CDCl3
Ablient Temperature
UNITY-400 "vvrssse"
PULSE SEQUENCE: apt
Relax, delay 4.000 sec
1st pulse 250.0 degrees
2nd pulse 180.0 degrees
Acq. Time 1.205 sec
Width 2713.2 Hz
180° repetition
DECOUPLER Freq. 180.5671512 MHz
DECOUPLE H1, 180.567151241 MHz
High power 50
on during acquisition
With 100% polarization
DATA PROCESSING
Line broadening 8.5 Hz
Gauss window 0.500 sec
Integration time 1.000 sec
FID size 331024
Total time 2 hr, 51 min, 39 sec

```



STANDARD PROTON PARAMETERS
 Pulse Sequence: *slpul*
 Solvent: CDCl₃
 Ambient Temperature
 EMWA-400 "Inovate400"



Relax. delay 1.000 sec
 Pulse 90.0 degrees
 Acq. time 3.000 sec
 Width 6000.0 Hz
 16 repetitions
 OBSERVE FREQ: 293.8723148 MHz
 DATA PROCESSING
 Line broadening 0.4 Hz
 FT size 131072
 Total time 1 min, 4 sec



13C OBSERVE

Jun 23 2004


Pulse Sequence: *apt*
 Solvent: CDCl₃
 Ambient Temperature
 UNITY-400 "Inovate400"
 PULSE SEQUENCE: *apt*
 Relax. delay 4.000 sec
 1st pulse 180.0 degrees
 2nd pulse 90.0 degrees
 Acq. time 1.200 sec
 Width 2712.4 Hz
 88 repetitions
 OBSERVE FREQ: 130.100.5671512 MHz
 DECOUPLE FREQ: 130.0511541 MHz
 High power 50
 on during acquisition
 Water presaturation
 Water is modulated
 DATA PROCESSING
 Line broadening 0.5 Hz
 Gauss window 0.000 sec
 FID window 0.100 sec
 FT size 131072
 Total time 8 min, 50 sec



STANDARD PROTON PARAMETERS
 Pulse Sequence: *z2pul*
 Solvent: CDCl₃
 Ambient temperature:
 INNOVA-400 "Inovatech"

Relax. delay 1.000 sec
 Pulse 90.4 degrees
 Acq. time 1.000 sec
 Width 3000.0 Hz
 16 repetitions
 OBSERVE: H1, 395.8723148 MHz
 DATA PROCESSING
 Line broadening 0.4 Hz
 FT size 131072
 Total time 1 min, 4 sec


Jun 10 2004



13C OBSERVE

Pulse Sequence: *apt*
 Solvent: CDCl₃
 Ambient temperature
 UNITY-400 "Inovatech"
 PULSE SEQUENCE: *apt*
 Relax. delay 4.000 sec
 1st pulse 130.0 degrees
 2nd pulse 130.0 degrees
 Acq. time 1.205 sec
 Width 27192.4 Hz
 32768 points
 OBSERVE: C13, 128.5671512 MHz
 DECOUPLE: H1, 395.8711441 MHz
 H1 decouple on
 on during acquisition
 VALZ-16 modulated
 DATA PROCESSING
 Line broadening 0.5 Hz
 Gauss window 0.500 sec
 center at 0.000 sec
 FT size 131072
 Total time 30 min, 42 sec

Jun 11 2004




STANDARD PROTON PARAMETERS
Pulse Sequence: **s2out**
Solvent: **CDCl₃**
Ambient temperature
Pile: **AldotForMetathesis**
[NOVA-60] "Inova60"
[NOVA-60] "Inova60"


```

Relax. delay 1.000 sec
Pulse 28.4 degrees
Acq. Time 3.000 sec.
Width 3000.0 Hz
16 repetitions
DESERVE HI, 518-8723148
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131472
Total time 1 min, 4 sec

```



13





```

13C OBSERVE



Pulse Sequence: apt
Solvvent: CDCl3
Ambient temperature
UNITY-400: "vxx4dd"
PULSE SEQUENCE: apt
Pulse width: 1.000 sec
1st pulse: 180.0 degrees
2nd pulse: 39.8 degrees
Acp: 1.295 sec
T1: 27.01 sec
n1: 64 repetitions
OBSERVE1: C13, 100 5671512
OBSERVE2: C13, 100 5671512
High power: Es
On during acquisition
WALTZ-16 modulated
Pulse width: 1.000 sec
Line broadening: 1.5 Hz
Gauss width: 0.500 sec
center at: 0.160 sec
Total time: 189.35 min. 48 sec

```



STANDARD PROTON PARAMETERS
 Pulse Sequence: s2pul
 Solvent: CDCl₃
 Ambient temperature
 INNOVA-600 "Inova600"

Relax. delay 1.000 sec
 Pulse 28.4 degrees
 Acc. time 0.05 sec
 Width 0.60 Hz
 16 repetitions
 OBSERVE FID, 598.0723148 MHz
 DATA PROCESSING
 Line broadening 0.4 Hz
 FT size 131072
 Total time 1 min, 4 sec





STANDARD PROTON PARAMETERS
Pulse Sequence: 62pu1
Solvent: CDCl3
Ambient temperature
INOVA-600 "Inova600"

```

Relax. delay 1.000 sec
Pulse 25.4 degrees
Acc. time 3.000 sec
Width 500.0 Hz
16 repetitions
OBSERVE H1, 593.8723148
DATA PROCESSING
Line broadening 0.4 Hz
FT size 131072
Total time 1 min, 4 sec

```

Jun 27 2004





STANDARD PROTON PARAMETERS
Pulse Sequence: s2pu1
Solvent: CDCl3
Ambient temperature
File: PinnickofMetathesis
INOVA-S80 "inova80"

```

Relax, delay 1.000 sec
Pulse 28.4 degrees
Acc. time 3.000 sec
With 80000 s Hz
15 repetitions
OBSERVE HI 598.6723148 MHz
DATA PROCESSING
Line broadening 8.4 Hz
FT size 151872
Total time 1 min, 6 sec





```


Jun 28 1964







BBC OBSERV



June 28 2004


















































13C OBSERVE





Jun 29 2004





May 15, 2005



















STANDARD PROTON PARAMETERS
 Pulse sequence: zgppr1
 Solvent: CDCl₃
 Ambient temperature
 File: 32a_Cyclopentenylacetanide
 INOVA-300 "Inovadess"
 Relax. delay 1.000 sec
 Pulse 26.4 degrees
 Acq. time 3.000 sec
 With 16 scans
 64 repetitions
 OBSERVE: H1, 59.5723140 MHz
 DATA PROCESSING: 0.4 Hz
 FT size: 32767
 Total time 4 min, 16 sec















Figure 1S. Cytotoxicity data for compound **1b** against the NCI in vitro 60 cell line human tumor screen (Dose Response curves).





Figure 2S. Cytotoxicity data for compound **1b** against the NCI in vitro 60 cell line human tumor screen (In-Vitro Activity).

National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results															
NSC : D - 742992 / 1				Experiment ID : 0610NS24								Test Type : 08		Units : Molar	
Report Date : December 29, 2006				Test Date : October 16, 2006								QNS :		MC :	
COMI : MA-3 (54947)				Stain Reagent : SRB Dual-Pass Related								SSPL : OSHE			
Log10 Concentration															
Panel/Cell Line	Time	Zero	Ctrl	Mean Optical Densities				Percent Growth				GI50	TGI	LC50	
				-8.8	-7.8	-6.8	-5.8	-4.8	-8.8	-7.8	-6.8	-5.8	-4.8		
Leukemia															
CCRF-CEM	0.207	0.904	0.819	0.082	0.131	0.111	0.299	88	-60	-37	-47	13	2.70E-9		
HL-60(TB)	0.331	1.505	1.539	1.361	1.054	0.652	0.571	103	88	62	27	20	3.27E-7	> 1.50E-5	> 1.50E-5
K-562	0.154	1.069	1.095	1.054	1.023	0.913	0.388	103	98	95	83	26	5.62E-6	> 1.50E-5	> 1.50E-5
RPMI-8226	0.889	2.412	2.098	2.176	2.005	2.154	1.769	79	84	73	83	58	> 1.50E-5	> 1.50E-5	> 1.50E-5
SR	0.149	0.443	0.326	0.219	0.177	0.135	0.074	60	24	9	-10	-51	2.85E-9	4.64E-7	1.44E-5
Non-Small Cell Lung Cancer															
A549/ATCC	0.472	2.076	2.199	2.251	2.211	2.208	1.906	108	111	108	108	89	> 1.50E-5	> 1.50E-5	> 1.50E-5
EKVK	0.446	1.187	1.198	1.250	1.275	1.282	1.004	102	109	112	113	75	> 1.50E-5	> 1.50E-5	> 1.50E-5
HOP-62	0.534	1.631	1.649	1.568	1.527	1.539	1.417	102	94	91	92	80	> 1.50E-5	> 1.50E-5	> 1.50E-5
HOP-92	0.626	0.934	0.928	0.889	0.888	0.874	0.833	98	85	85	81	67	> 1.50E-5	> 1.50E-5	> 1.50E-5
NCI-H226	0.841	1.926	1.983	2.011	1.997	2.073	1.763	105	108	107	114	85	> 1.50E-5	> 1.50E-5	> 1.50E-5
NCI-H23	0.442	1.183	1.154	1.208	1.375	1.177	1.035	96	103	126	99	80	> 1.50E-5	> 1.50E-5	> 1.50E-5
NCI-H322M	0.521	1.213	1.215	1.239	1.193	1.270	1.160	100	104	97	108	92	> 1.50E-5	> 1.50E-5	> 1.50E-5
NCI-H460	0.309	2.133	2.208	2.210	2.238	2.276	2.163	104	104	106	106	102	> 1.50E-5	> 1.50E-5	> 1.50E-5
NCI-H522	0.716	1.624	1.568	1.490	1.588	1.543	1.232	94	85	96	91	57	> 1.50E-5	> 1.50E-5	> 1.50E-5
Colon Cancer															
COLO 205	0.290	0.741	0.735	0.683	0.658	0.638	0.436	99	87	82	77	32	6.04E-6	> 1.50E-5	> 1.50E-5
HCC-2998	0.639	0.997	0.919	0.988	0.899	0.939	0.780	78	97	72	84	39	8.59E-6	> 1.50E-5	> 1.50E-5
HCT-116	0.148	1.472	1.318	1.472	1.369	1.445	0.867	88	100	92	98	54	> 1.50E-5	> 1.50E-5	> 1.50E-5
HCT-15	0.214	1.956	2.011	1.959	1.916	1.920	1.720	103	100	98	98	86	> 1.50E-5	> 1.50E-5	> 1.50E-5
HT29	0.213	1.227	1.157	1.191	1.219	1.211	1.083	93	96	99	98	86	> 1.50E-5	> 1.50E-5	> 1.50E-5
KM12	0.447	1.511	1.567	1.587	1.709	1.601	1.577	105	107	119	109	106	> 1.50E-5	> 1.50E-5	> 1.50E-5
SW-620	0.202	1.415	1.474	1.403	1.332	1.839	1.175	105	99	93	135	80	> 1.50E-5	> 1.50E-5	> 1.50E-5
CNS Cancer															
SF-268	0.466	1.504	1.542	1.465	1.456	1.482	1.382	104	96	95	98	88	> 1.50E-5	> 1.50E-5	> 1.50E-5
SF-295	0.605	2.223	2.276	2.178	2.074	2.152	2.079	103	97	91	96	91	> 1.50E-5	> 1.50E-5	> 1.50E-5
SF-539	0.542	1.561	1.617	1.679	1.593	1.644	1.699	106	112	103	108	114	> 1.50E-5	> 1.50E-5	> 1.50E-5
SNB-19	0.795	2.866	2.782	2.607	2.487	2.503	2.167	96	87	82	82	66	> 1.50E-5	> 1.50E-5	> 1.50E-5
SNB-75	0.270	0.561	0.571	0.584	0.562	0.563	0.506	103	108	100	101	81	> 1.50E-5	> 1.50E-5	> 1.50E-5
U251	0.332	1.811	1.899	1.897	1.860	1.893	1.818	106	106	103	106	100	> 1.50E-5	> 1.50E-5	> 1.50E-5
Melanoma															
LOX IMVI	0.301	2.263	2.343	2.235	2.236	2.249	2.104	104	99	99	99	92	> 1.50E-5	> 1.50E-5	> 1.50E-5
MALME-3M	0.528	0.862	0.862	0.856	0.895	0.832	0.777	100	98	110	91	74	> 1.50E-5	> 1.50E-5	> 1.50E-5
M14	0.348	1.374	1.229	1.341	1.270	1.324	1.259	86	97	90	95	89	> 1.50E-5	> 1.50E-5	> 1.50E-5
SK-MEL-2	0.581	1.134	1.181	1.148	1.159	1.116	1.116	108	103	104	97	97	> 1.50E-5	> 1.50E-5	> 1.50E-5
SK-MEL-28	0.373	1.118	1.138	1.132	1.101	1.086	0.975	103	102	98	96	81	> 1.50E-5	> 1.50E-5	> 1.50E-5
SK-MEL-5	0.290	1.310	1.378	1.416	1.285	1.304	1.084	107	110	98	99	78	> 1.50E-5	> 1.50E-5	> 1.50E-5
UACC-257	0.929	1.958	2.021	2.098	2.014	2.006	1.840	106	114	105	105	89	> 1.50E-5	> 1.50E-5	> 1.50E-5
UACC-62	0.720	2.330	2.359	2.465	2.424	2.530	2.104	102	108	106	112	86	> 1.50E-5	> 1.50E-5	> 1.50E-5
Ovarian Cancer															
IGROV1	0.287	1.016	1.054	0.994	0.929	1.026	0.611	105	97	88	101	44	1.20E-5	> 1.50E-5	> 1.50E-5
OVCAR-3	0.373	1.555	1.529	1.442	1.343	1.479	1.042	98	90	82	94	57	> 1.50E-5	> 1.50E-5	> 1.50E-5
OVCAR-4	0.362	0.861	0.881	0.918	0.901	0.915	0.719	104	111	108	111	72	> 1.50E-5	> 1.50E-5	> 1.50E-5
OVCAR-5	0.771	2.104	2.084	2.022	1.989	1.955	1.652	98	94	91	89	66	> 1.50E-5	> 1.50E-5	> 1.50E-5
OVCAR-8	0.429	1.713	1.762	1.842	1.852	1.808	1.651	104	110	111	107	95	> 1.50E-5	> 1.50E-5	> 1.50E-5
SK-OV-3	0.753	1.202	1.192	1.170	1.184	1.168	1.139	98	93	96	92	86	> 1.50E-5	> 1.50E-5	> 1.50E-5
Renal Cancer															
786-0	0.659	2.611	2.633	2.489	2.553	2.625	2.526	101	94	97	101	96	> 1.50E-5	> 1.50E-5	> 1.50E-5
A498	0.845	1.453	1.454	1.466	1.457	1.442	1.403	100	102	101	98	92	> 1.50E-5	> 1.50E-5	> 1.50E-5
ACHN	0.332	1.741	1.726	1.741	1.726	1.713	1.528	99	100	99	98	85	> 1.50E-5	> 1.50E-5	> 1.50E-5
CAKI-1	0.640	1.769	1.820	1.655	1.617	1.732	1.294	104	90	87	97	58	> 1.50E-5	> 1.50E-5	> 1.50E-5
RFX 393	0.828	1.403	1.429	1.378	1.436	1.393	1.303	105	96	106	98	83	> 1.50E-5	> 1.50E-5	> 1.50E-5
SN12C	0.445	1.524	1.621	1.640	1.692	1.659	1.524	109	111	115	112	100	> 1.50E-5	> 1.50E-5	> 1.50E-5
TK-10	0.609	1.096	1.163	1.191	1.195	1.209	1.134	114	120	120	123	108	> 1.50E-5	> 1.50E-5	> 1.50E-5
UO-31	0.288	1.336	1.344	1.269	1.264	1.218	0.973	101	94	93	89	65	> 1.50E-5	> 1.50E-5	> 1.50E-5
Prostate Cancer															
PC-3	0.265	1.012	1.078	0.994	1.006	0.961	0.855	109	97	99	93	79	> 1.50E-5	> 1.50E-5	> 1.50E-5
DU-145	0.190	0.782	0.809	0.815	0.792	0.805	0.733	105	106	102	104	92	> 1.50E-5	> 1.50E-5	> 1.50E-5
Breast Cancer															



SI References:

- [1] P. K. Jadhav, K. S. Bhat, P. T. Perumal, H. C. Brown, *J. Org. Chem.* **1986**, *51*, 432-439.
- [2] W. J. Gensler, F. Johnson, A. Sloan, *J. Am. Chem. Soc* **1960**, *82*, 6074-6081.
- [3] D. V. Patel, F. VanMiddlesworth, J. Donaubauer, C. Sih, *J. Am. Chem. Soc.* **1986**, *108*, 4603-4614.
- [4] D. Schinzer, A. Bauer, J. Schieber, *Chem. Eur. J.* **1999**, *5*, 2492-2500.
- [5] K. C. Nicolaou, S. Ninkovic, F. Sarabia, D. Vourloumis, Y. He, H. Vallberg, M. R. Finlay, Z. Yang, *J. Am. Chem. Soc.* **1997**, *119*, 7974-7991.